Paul Ainsworth leads the ITC practice at Sterne, Kessler, Goldstein & Fox PLLC , where he frequently advises clients from the life sciences, pharma and biotech sectors. Businesses turn to Ainsworth for counsel on patents and trade secrets, and support with trials and regulatory matters. He has particular proficiency in handling Hatch-Waxman litigation, advising on both innovative and generic drugs. Ainsworth is also equipped to support with contentious proceedings, arbitration and transactions, leveraging his scientific background.
Legal 500 Editorial commentary
Accolades
Washington DC Elite
Profile
Position
Director
Career
Paul A. Ainsworth, a director in Sterne Kessler’s Trial & Appellate Practice Group, is a first-chair trial attorney with a practice focused on patent and trade secret disputes in federal district courts, at the U.S. International Trade Commission (ITC), and before the U.S. Court of Appeals for the Federal Circuit. Paul’s clients include established and emerging leaders in the pharmaceutical, biopharmaceutical, medical devices, chemical manufacturing, and consumer products industries.
Education
- J.D., William & Mary Law School
- B.A., Political Science, The George Washington University
Content supplied by Sterne, Kessler, Goldstein & Fox PLLC
Key clients
- Wirtgen America, Inc.
- Catalyst Pharmaceuticals, Inc.
Work highlights
Representing Catalyst Pharmaceuticals, a biopharma company developing treatment for rare diseases, in several ANDA litigation proceedings.